ID   SCYL2_HUMAN             Reviewed;         929 AA.
AC   Q6P3W7; A8KAB5; Q96EF4; Q96ST4; Q9H7V5; Q9NVH3; Q9P2I7;
DT   17-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   12-OCT-2022, entry version 166.
DE   RecName: Full=SCY1-like protein 2 {ECO:0000305};
DE   AltName: Full=Coated vesicle-associated kinase of 104 kDa {ECO:0000303|PubMed:15809293};
GN   Name=SCYL2 {ECO:0000312|HGNC:HGNC:19286};
GN   Synonyms=CVAK104 {ECO:0000303|PubMed:15809293}, KIAA1360
GN   {ECO:0000312|EMBL:BAA92598.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-357.
RC   TISSUE=Teratocarcinoma, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Carcinoma, and Leiomyosarcoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 138-929.
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI. The
RT   complete sequences of 150 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [5]
RP   FUNCTION, INTERACTION WITH CLATHRIN AND AP2 COMPLEX, AUTOPHOSPHORYLATION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=15809293; DOI=10.1074/jbc.m502462200;
RA   Conner S.D., Schmid S.L.;
RT   "CVAK104 is a novel poly-L-lysine-stimulated kinase that targets the beta2-
RT   subunit of AP2.";
RL   J. Biol. Chem. 280:21539-21544(2005).
RN   [6]
RP   FUNCTION, INTERACTION WITH CLATHRIN AND AP2 COMPLEX, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16914521; DOI=10.1091/mbc.e06-05-0390;
RA   Duewel M., Ungewickell E.J.;
RT   "Clathrin-dependent association of CVAK104 with endosomes and the trans-
RT   Golgi network.";
RL   Mol. Biol. Cell 17:4513-4525(2006).
RN   [7]
RP   INTERACTION WITH AP2B1.
RX   PubMed=16903783; DOI=10.1371/journal.pbio.0040262;
RA   Schmid E.M., Ford M.G.J., Burtey A., Praefcke G.J.K., Peak-Chew S.-Y.,
RA   Mills I.G., Benmerah A., McMahon H.T.;
RT   "Role of the AP2 beta-appendage hub in recruiting partners for clathrin-
RT   coated vesicle assembly.";
RL   PLoS Biol. 4:E262-E262(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-677, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-677 AND THR-708, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-357; SER-720 AND HIS-863.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [12]
RP   INVOLVEMENT IN AMC4, AND VARIANT AMC4 36-ARG--GLY-929 DEL.
RX   PubMed=31960134; DOI=10.1007/s00439-020-02117-7;
RA   Seidahmed M.Z., Al-Kindi A., Alsaif H.S., Miqdad A., Alabbad N., Alfifi A.,
RA   Abdelbasit O.B., Alhussein K., Alsamadi A., Ibrahim N., Al-Futaisi A.,
RA   Al-Maawali A., Alkuraya F.S.;
RT   "Recessive mutations in SCYL2 cause a novel syndromic form of
RT   arthrogryposis in humans.";
RL   Hum. Genet. 139:513-519(2020).
CC   -!- FUNCTION: Component of the AP2-containing clathrin coat that may
CC       regulate clathrin-dependent trafficking at plasma membrane, TGN and
CC       endosomal system (Probable). A possible serine/threonine-protein kinase
CC       toward the beta2-subunit of the plasma membrane adapter complex AP2 and
CC       other proteins in presence of poly-L-lysine has not been confirmed
CC       (PubMed:15809293, PubMed:16914521). By regulating the expression of
CC       excitatory receptors at synapses, plays an essential role in neuronal
CC       function and signaling and in brain development (By similarity).
CC       {ECO:0000250|UniProtKB:Q8CFE4, ECO:0000269|PubMed:15809293,
CC       ECO:0000269|PubMed:16914521, ECO:0000305|PubMed:15809293,
CC       ECO:0000305|PubMed:16914521}.
CC   -!- SUBUNIT: Interacts with clathrin and AP2B1; the interaction mediates
CC       the association with the AP-2 complex. {ECO:0000269|PubMed:15809293,
CC       ECO:0000269|PubMed:16903783, ECO:0000269|PubMed:16914521}.
CC   -!- INTERACTION:
CC       Q6P3W7; O14640: DVL1; NbExp=4; IntAct=EBI-1046810, EBI-723489;
CC       Q6P3W7; Q13467: FZD5; NbExp=4; IntAct=EBI-1046810, EBI-3913027;
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, clathrin-coated vesicle
CC       {ECO:0000269|PubMed:15809293, ECO:0000269|PubMed:16914521}. Golgi
CC       apparatus, trans-Golgi network membrane {ECO:0000269|PubMed:16914521}.
CC       Endosome membrane {ECO:0000269|PubMed:16914521}. Note=Colocalizes to
CC       the trans-Golgi network (TGN) and to endosomal membranes with clathrin,
CC       transferrin and plasma membrane adapter AP1 and AP3 complexes.
CC       {ECO:0000269|PubMed:16914521}.
CC   -!- PTM: Could autophosphorylate in presence of poly-L-lysine.
CC       {ECO:0000269|PubMed:15809293}.
CC   -!- DISEASE: Arthrogryposis multiplex congenita 4, neurogenic, with
CC       agenesis of the corpus callosum (AMC4) [MIM:618766]: A form of
CC       arthrogryposis multiplex congenita, a developmental condition
CC       characterized by multiple joint contractures resulting from reduced or
CC       absent fetal movements. AMC4 is an autosomal recessive, severe form
CC       with onset in utero. Patients manifest little or no fetal movements,
CC       significant contractures affecting the upper and lower limbs,
CC       dysmorphic facial features, optic atrophy, limb fractures, profound
CC       global developmental delay, seizures, and peripheral neuropathy. Many
CC       patients die in early childhood. {ECO:0000269|PubMed:31960134}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA91778.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB14869.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB55194.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK001597; BAA91778.1; ALT_INIT; mRNA.
DR   EMBL; AK024274; BAB14869.1; ALT_INIT; mRNA.
DR   EMBL; AK027551; BAB55194.1; ALT_INIT; mRNA.
DR   EMBL; AK292980; BAF85669.1; -; mRNA.
DR   EMBL; CH471054; EAW97633.1; -; Genomic_DNA.
DR   EMBL; BC012387; AAH12387.3; -; mRNA.
DR   EMBL; BC063798; AAH63798.1; -; mRNA.
DR   EMBL; AB037781; BAA92598.1; -; mRNA.
DR   CCDS; CCDS9076.1; -.
DR   RefSeq; NP_001304713.1; NM_001317784.1.
DR   RefSeq; NP_001317182.1; NM_001330253.1.
DR   RefSeq; NP_001317183.1; NM_001330254.1.
DR   RefSeq; NP_001317185.1; NM_001330256.1.
DR   RefSeq; NP_060458.3; NM_017988.5.
DR   AlphaFoldDB; Q6P3W7; -.
DR   SMR; Q6P3W7; -.
DR   BioGRID; 120810; 146.
DR   CORUM; Q6P3W7; -.
DR   IntAct; Q6P3W7; 44.
DR   MINT; Q6P3W7; -.
DR   STRING; 9606.ENSP00000354061; -.
DR   GlyGen; Q6P3W7; 6 sites, 1 O-linked glycan (6 sites).
DR   iPTMnet; Q6P3W7; -.
DR   MetOSite; Q6P3W7; -.
DR   PhosphoSitePlus; Q6P3W7; -.
DR   BioMuta; SCYL2; -.
DR   DMDM; 74762350; -.
DR   EPD; Q6P3W7; -.
DR   jPOST; Q6P3W7; -.
DR   MassIVE; Q6P3W7; -.
DR   MaxQB; Q6P3W7; -.
DR   PaxDb; Q6P3W7; -.
DR   PeptideAtlas; Q6P3W7; -.
DR   PRIDE; Q6P3W7; -.
DR   ProteomicsDB; 66937; -.
DR   Antibodypedia; 17837; 173 antibodies from 24 providers.
DR   DNASU; 55681; -.
DR   Ensembl; ENST00000360820.7; ENSP00000354061.2; ENSG00000136021.19.
DR   GeneID; 55681; -.
DR   KEGG; hsa:55681; -.
DR   MANE-Select; ENST00000360820.7; ENSP00000354061.2; NM_017988.6; NP_060458.3.
DR   UCSC; uc001thn.4; human.
DR   CTD; 55681; -.
DR   DisGeNET; 55681; -.
DR   GeneCards; SCYL2; -.
DR   HGNC; HGNC:19286; SCYL2.
DR   HPA; ENSG00000136021; Low tissue specificity.
DR   MalaCards; SCYL2; -.
DR   MIM; 616365; gene.
DR   MIM; 618766; phenotype.
DR   neXtProt; NX_Q6P3W7; -.
DR   OpenTargets; ENSG00000136021; -.
DR   PharmGKB; PA134887807; -.
DR   VEuPathDB; HostDB:ENSG00000136021; -.
DR   eggNOG; KOG2137; Eukaryota.
DR   GeneTree; ENSGT00880000138031; -.
DR   InParanoid; Q6P3W7; -.
DR   OrthoDB; 196028at2759; -.
DR   PhylomeDB; Q6P3W7; -.
DR   TreeFam; TF314178; -.
DR   PathwayCommons; Q6P3W7; -.
DR   SignaLink; Q6P3W7; -.
DR   BioGRID-ORCS; 55681; 19 hits in 1112 CRISPR screens.
DR   ChiTaRS; SCYL2; human.
DR   GeneWiki; SCYL2; -.
DR   GenomeRNAi; 55681; -.
DR   Pharos; Q6P3W7; Tbio.
DR   PRO; PR:Q6P3W7; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q6P3W7; protein.
DR   Bgee; ENSG00000136021; Expressed in mucosa of sigmoid colon and 181 other tissues.
DR   ExpressionAtlas; Q6P3W7; baseline and differential.
DR   Genevisible; Q6P3W7; HS.
DR   GO; GO:0030136; C:clathrin-coated vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:InterPro.
DR   GO; GO:0004672; F:protein kinase activity; IEA:InterPro.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL.
DR   GO; GO:0007420; P:brain development; ISS:UniProtKB.
DR   GO; GO:0008333; P:endosome to lysosome transport; IDA:BHF-UCL.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:2000370; P:positive regulation of clathrin-dependent endocytosis; IDA:BHF-UCL.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0021860; P:pyramidal neuron development; ISS:UniProtKB.
DR   GO; GO:2000286; P:receptor internalization involved in canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   Coiled coil; Cytoplasmic vesicle; Disease variant; Endosome;
KW   Golgi apparatus; Membrane; Phosphoprotein; Reference proteome.
FT   CHAIN           1..929
FT                   /note="SCY1-like protein 2"
FT                   /id="PRO_0000252446"
FT   DOMAIN          32..327
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REPEAT          443..479
FT                   /note="HEAT"
FT   REGION          684..709
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          699..929
FT                   /note="Necessary for interaction with AP2 complex and
FT                   clathrin, interaction with clathrin is necessary for its
FT                   targeting to the TGN and endosomal membranes"
FT   REGION          906..929
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          661..701
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        693..709
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         677
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         708
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VARIANT         36..929
FT                   /note="Missing (in AMC4)"
FT                   /evidence="ECO:0000269|PubMed:31960134"
FT                   /id="VAR_083876"
FT   VARIANT         357
FT                   /note="P -> L (in dbSNP:rs33968174)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041368"
FT   VARIANT         720
FT                   /note="T -> S (in dbSNP:rs763873645)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041369"
FT   VARIANT         863
FT                   /note="Q -> H (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041370"
FT   CONFLICT        139..145
FT                   /note="PISPDIK -> LMSGDIG (in Ref. 4; BAA92598)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        186
FT                   /note="L -> S (in Ref. 1; BAB14869)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        424
FT                   /note="Q -> QASNM (in Ref. 4; BAA92598)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        439
FT                   /note="K -> R (in Ref. 1; BAB14869)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        554
FT                   /note="F -> L (in Ref. 3; AAH12387)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        628
FT                   /note="Q -> R (in Ref. 1; BAB14869)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        638
FT                   /note="T -> I (in Ref. 3; AAH12387)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        747
FT                   /note="T -> A (in Ref. 1; BAA91778)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   929 AA;  103709 MW;  980B481BF7044628 CRC64;
     MESMLNKLKS TVTKVTADVT SAVMGNPVTR EFDVGRHIAS GGNGLAWKIF NGTKKSTKQE
     VAVFVFDKKL IDKYQKFEKD QIIDSLKRGV QQLTRLRHPR LLTVQHPLEE SRDCLAFCTE
     PVFASLANVL GNWENLPSPI SPDIKDYKLY DVETKYGLLQ VSEGLSFLHS SVKMVHGNIT
     PENIILNKSG AWKIMGFDFC VSSTNPSEQE PKFPCKEWDP NLPSLCLPNP EYLAPEYILS
     VSCETASDMY SLGTVMYAVF NKGKPIFEVN KQDIYKSFSR QLDQLSRLGS SSLTNIPEEV
     REHVKLLLNV TPTVRPDADQ MTKIPFFDDV GAVTLQYFDT LFQRDNLQKS QFFKGLPKVL
     PKLPKRVIVQ RILPCLTSEF VNPDMVPFVL PNVLLIAEEC TKEEYVKLIL PELGPVFKQQ
     EPIQILLIFL QKMDLLLTKT PPDEIKNSVL PMVYRALEAP SIQIQELCLN IIPTFANLID
     YPSMKNALIP RIKNACLQTS SLAVRVNSLV CLGKILEYLD KWFVLDDILP FLQQIPSKEP
     AVLMGILGIY KCTFTHKKLG ITKEQLAGKV LPHLIPLSIE NNLNLNQFNS FISVIKEMLN
     RLESEHKTKL EQLHIMQEQQ KSLDIGNQMN VSEEMKVTNI GNQQIDKVFN NIGADLLTGS
     ESENKEDGLQ NKHKRASLTL EEKQKLAKEQ EQAQKLKSQQ PLKPQVHTPV ATVKQTKDLT
     DTLMDNMSSL TSLSVSTPKS SASSTFTSVP SMGIGMMFST PTDNTKRNLT NGLNANMGFQ
     TSGFNMPVNT NQNFYSSPST VGVTKMTLGT PPTLPNFNAL SVPPAGAKQT QQRPTDMSAL
     NNLFGPQKPK VSMNQLSQQK PNQWLNQFVP PQGSPTMGSS VMGTQMNVIG QSAFGMQGNP
     FFNPQNFAQP PTTMTNSSSA SNDLKDLFG
//
